John B. Buse, M.D., Ph.D. is the Verne S. Caviness Distinguished Professor of Medicine, Director of the Diabetes Care Center, Chief of the Division of Endocrinology and Executive Associate Dean of Clinical research at UNC, where he is the principal investigator on numerous studies in the prevention and treatment of type 1 and type 2 diabetes mellitus. Dr. Buse served as President of Medicine and Science for the American Diabetes Association in 2008, and in 2011 he was appointed as Chair of the National Diabetes Education Program. Dr. Buse has authored more than 200 publications and received numerous awards and honors.

Dr. Stanley Hsia is an Associate Professor of Medicine at Charles R. Drew University of Medicine and Science, and a Health Sciences Associate Clinical Professor at the David Geffen School of Medicine at UCLA, Los Angeles, CA. He completed his medical school at the University of Toronto, Canada, Internal Medicine residency at Queen's University, Endocrinology Fellowship at the University of Toronto, and did postdoctoral research at the University of California, San Diego. He is certified in Endocrinology & Metabolism by both the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada, and is a Fellow of the American College of Endocrinology as well as a Diplomate of the American Board of Clinical Lipidology. He currently teaches in the Charles R. Drew University-UCLA medicine program, serves as a Clinical Trials Principal Investigator with the National Research Institute (NRI) in Los Angeles and Santa Ana, CA, and practices as a clinical endocrinologist with the Southern California Endocrine Group in Orange, CA. His academic interests focus on insulin resistance and its related conditions, including obesity, diabetes, and dyslipidemia. He has received research grants from the NIH and the American Diabetes Association, and has published numerous original research studies, review articles, CME programs, and book chapters, as well as presenting his research at numerous national and international meetings.

Vivian A. Fonseca, M.D., F.R.C.P. is Professor of Medicine and Alumni Chair in Diabetes in the Section of Endocrinology, at Tulane University’s Health Sciences Center. He is the principal investigator of the DRMS (diabetes remote management system) study, which is designed to evaluate the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with type 2 diabetes. Dr. Fonseca has conducted trials for most diabetes drugs on the market. A former President of Medicine and Science for the American Diabetes Association, he is editor-in-chief of the Journal of Diabetes Complications and has served as editor-in-chief of Diabetes Care and the Journal of the Metabolic Syndrome and Related Disorders.

Richard A. Kahn, Ph.D. is an independent consultant/researcher and clinical professor of medicine at the University of North Carolina School of Medicine. A senior staff member of the American Diabetes Association from 1985 until his retirement from the Association in 2009, Dr. Kahn was the Chief Scientific and Medical Officer and was responsible for all the scientific and medical affairs of the Association. Dr. Kahn established the first tissue bank in the Red Cross System and directed a large research laboratory concerned with the pathophysiology of blood cells and the prevention of transfusion-transmitted diseases.

Gary Hutchinson is an entrepreneurial executive with more than 25 years in healthcare technology. He is the CEO of ThelioPulse, a spinoff company from the Alfred E. Mann Institute at the University of Southern California (AMI USC), where he is Entrepreneur in Residence. He is also an Adjunct Lecturer at the UCLA Anderson School of Management/Global Access Program. Mr. Hutchinson served as President and CEO of Precision Dynamics Corporation from 2002 to 2010, and under his leadership the company grew from $43 million to $112 million in sales and $2 million to $16 million in EBITDA. Before Precision Dynamics Corporation, he was a founder of Zymed Medical Systems (now Phillips Medical Systems), which became the leader in ambulatory monitoring and arrhythmia algorithms and grew to $25 million in sales and $5 million in EBITDA. After its acquisition in 2000, he served as VP of Phillips’ $200 million Cardiology Products unit. Mr. Hutchinson has experience on the advisory boards of a number of companies, including ORFID, an early-stage company in organic semiconductors and polymer-based radio frequency identification devices at UCLA. He has served on the board of directors for AdvaMed, a healthcare industry advocacy organization; Quinton Instruments, a leader in stress testing; and Cardiac Rehab and Cardiac Imaging Systems. As an investor with HP, WR Hambrecht & Zymed, he led a buyout of Quinton from American Home Products.

Scott Fuller, FACHE is Senior Vice President of Joint Ventures and Alliances at Seton Healthcare Family. He joined Seton in 2006 as Vice President and Chief Operating Officer for Seton Highland Lakes Hospital and its health centers. During his tenure with Seton, he went on to run both Seton Highland Lakes and Seton Northwest Hospitals. After serving as Assistant Executive Director of Financial Planning for Scott & White Health, he also served as Director of Strategic and Financial Planning for Phoenix Children’s Hospital. His financial background spans investment banking with Shattuck Hammond Partners, Inc., including mergers, acquisitions and divestitures, financial advisory and tax-exempt debt underwriting, commercial real estate and strategic capital planning. Fuller is a graduate of the Ascension Health Executive Formation Program, class of 2010. He earned his Bachelor of Science from Brigham Young University in 1992 and his Master of Health Services Administration in 1994 from Arizona State University, W.P. Carey School of Business.